News FAMHP

There are 24 result(s) found based on your search criteria

1-10 from 24 result(s)

Coronavirus: Belgium agrees on procurement of Janssen's (Johnson & Johnson) vaccine candidate

The European Commission is holding negotiations on behalf of the Member States for procurement procedures for COVID-19 vaccines and is presenting contracts to the Member States. In Belgium, the Advisory Committee responsible for the analysis of the procurement files issued a positive recommendation for Janssen's (Johnson & Johnson) vaccine candidate. The Interministerial Conference (IMC) for Public Health has followed the advice. Belgium will buy the vaccine if a marketing authorisation is granted.

Give your opinion on a genetically modified drug for the treatment of Duchenne muscular dystrophy

The FPS Public Health and FAMHP would like to invite you to take part in the public consultation on a clinical trial testing the genetically modified drug PF-06939926 for the treatment of Duchenne muscular dystrophy. The public consultation will run from 23 September 2020 to 23 October 2020.

Coronavirus: further extension of the measures taken by the FAMHP to avoid medicinal product shortages

On 1 April 2020, the FAMHP took steps regarding a range of medicinal products in order to avoid any shortage. These measures have now been extended by one month.

Influenza vaccination 2020-2021: sequential approach with priority for at-risk groups

COVID-19 makes it important to be able to vaccinate at-risk groups to the maximum extent possible in order to avoid overburdening the healthcare sector. Therefore, influenza vaccination for 2020-2021 will be phased in, giving priority to those at risk.

The COVID-19 serological tests bought by the government are reliable

Recent articles in the media have once again questioned the reliability of the serological tests bought by the government, in particular the DiaSorin test. The FAMHP is clear: on the basis of current scientific knowledge, this test meets all requirements and can be used without any problems.

Coronavirus – Evaluation of the use of saliva samples as an alternative to sampling via a deep nasal swab to detect SARS-CoV-2, the virus that causes COVID-19

Because of the benefits to both patients and healthcare professionals, a study on the use of saliva samples as an alternative to sampling via a deep nasal swab (nasopharyngeal) to detect SARS-CoV-2 using molecular detection tests (PCR) was launched on 28 May 2020.

Coronavirus and the fight led by the FAMHP: solutions implemented by the FAMHP in the face of medical equipment shortages

Since the start of the coronavirus pandemic, the FAMHP teams have been working relentlessly to support hospitals facing difficulties with supplies of medical devices. Here is an overview of the measures implemented by the FAMHP.

Coronavirus and the fight led by the FAMHP: the FAMHP facilitates and supports the development of COVID-19 treatments and vaccines

Since the start of the coronavirus pandemic, the FAMHP teams have devoted a lot of resources to monitoring and supporting clinical research on COVID-19. Here is an overview of the measures implemented by the FAMHP.

Coronavirus : first COVID-19 vaccine trial authorized in Belgium

The Federal Agency for Medicines and Health Products (FAMHP) has authorized the first clinical trial evaluating a vaccine against COVID-19 in Belgium. This is the candidate vaccine from the German biotech firm CureVac.

Postponement of the European regulation for medical devices due to of COVID-19

Because medical devices such as medical gloves, surgical masks, intensive care equipment and other medical equipment play a crucial role within the context of the COVID-19 pandemic, on 24 April 2020, the application date of various provisions of the European Regulation (Regulation 2017/745) on medical devices was postponed until 26 May 2021.

1-10 from 24 result(s)